公开(公告)号：US20050143441A1

公开(公告)日：2005-06-30

申请号：US11005486

申请日：2004-12-07

申请人： Jochen Antel ,  Gunter Krause ,  Peter-Colin Gregory ,  Michael Wurl ,  Harald Waldeck ,  Josephus Lange ,  Cornelis Kruse

发明人： Jochen Antel ,  Gunter Krause ,  Peter-Colin Gregory ,  Michael Wurl ,  Harald Waldeck ,  Josephus Lange ,  Cornelis Kruse

IPC分类号： A61K31/365 ,  A61K31/4152

CPC分类号： A61K31/4152 ,  A61K31/365 ,  A61K2300/00

摘要： The present invention relates to a novel medical use of e.g. 4,5-dihydro-1H-pyrazole compounds which are potent antagonists of the cannabis CB1-receptor in combination with lipase inhibitors. Said compounds are particularly suitable in combination with lipase inhibitors in the manufacture of medicaments for the treatment and/or prophylaxis of obesity in adolescent or in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as in adolescent patients. The compounds have the general formula (I) wherein the group Bb represents sulfonyl or carbonyl, and the substituents R, R1, R2 and R3, and the group Aa are defined as shown in the description. Preferred lipase inhibitors are orlistat, panclicins, ATL-962 and/or lipstatin.

摘要翻译： 本发明涉及一种新的医疗用途。 4,5-二氢-1H-吡唑化合物，其是大麻CB 1 - 受体与脂肪酶抑制剂组合的有效拮抗剂。 所述化合物在制备用于治疗和/或预防青少年或青少年患者肥胖症的药物和/或用于治疗和/或预防青少年药物诱导的肥胖症以及 青少年患者。 化合物具有通式（I），其中基团Bb表示磺酰基或羰基，取代基R 1，R 1，R 2和R 3， SUB>，并且组Aa如说明书所示定义。 优选的脂肪酶抑制剂是奥利司他，胰蛋白酶，ATL-962和/或脂抑素。

公开(公告)号：US20050124660A1

公开(公告)日：2005-06-09

申请号：US10969840

申请日：2004-10-22

申请人： Jochen Antel ,  Peter-Colin Gregory ,  Harald Waldeck ,  Gunter Krause ,  Josephus Lange ,  Cornelis Kruse

发明人： Jochen Antel ,  Peter-Colin Gregory ,  Harald Waldeck ,  Gunter Krause ,  Josephus Lange ,  Cornelis Kruse

IPC分类号： A61K31/4196 ,  A61K31/426 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/5377 ,  A61K31/541

CPC分类号： A61K31/4439 ,  A61K31/4196 ,  A61K31/426 ,  A61K31/454 ,  A61K31/5377 ,  A61K31/541

摘要： The present invention relates to a novel medical use of compounds with CB1-receptor activity selected from the group of 4,5-dihydro-1H-pyrazole derivatives, 1H-Imidazole derivatives, thiazole derivatives and/or 1H-1,2,4-triazole-3-carboxamide derivatives, as each defined in the specification, or of a prodrug thereof, a tautomer thereof or a salt thereof, in the manufacture of medicaments for the treatment and/or prophylaxis of CB1 receptor related diseases in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile, as well as in adolescent, patients. Furthermore, the invention pertains to the use of said compounds with CB1-receptor activity in combination with lipase inhibitors. Said compounds are particularly suitable in combination with lipase inhibitors in the manufacture of medicaments for the treatment and/or prophylaxis of obesity in adolescent or in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as in adolescent patients. Preferred lipase inhibitors are orlistat, panclicins, ATL-962 and/or lipstatin.

摘要翻译： 本发明涉及一种具有选自4,5-二氢-1H-吡唑衍生物，1H-咪唑衍生物，噻唑衍生物和/或其中之一种具有CB 1 - 1 - 受体活性的化合物的新型医疗用途 在制备用于治疗和/或预防CB的药物中的1H-1,2,4-三唑-3-甲酰胺衍生物，如说明书中所定义，或其前药，其互变异构体或其盐 少年患者中的受体相关疾病和/或用于治疗和/或预防青少年以及青少年患者的药物诱导的肥胖症。 此外，本发明涉及具有CB 1/2受体活性的所述化合物与脂肪酶抑制剂的组合的用途。 所述化合物在制备用于治疗和/或预防青少年或青少年患者肥胖症的药物和/或用于治疗和/或预防青少年药物诱导的肥胖症以及 青少年患者。 优选的脂肪酶抑制剂是奥利司他，胰蛋白酶，ATL-962和/或脂抑素。

公开(公告)号：US20050239859A2

公开(公告)日：2005-10-27

申请号：US10929377

申请日：2004-08-31

申请人： Jochen Antel ,  Gunter Krause ,  Josephus Lange ,  Cornelis Kruse ,  Peter-Colin Gregory ,  Cathaline Den Besten

发明人： Jochen Antel ,  Gunter Krause ,  Josephus Lange ,  Cornelis Kruse ,  Peter-Colin Gregory ,  Cathaline Den Besten

IPC分类号： A61K31/415

CPC分类号： A61K31/415

摘要： Abstract of the DisclosureThe present invention relates to a novel medical use of 4,5-dihydro-1H-pyrazole compounds which are potent antagonists of the cannabis CB1-receptor. Said compounds are particularly suitable in the manufacture of medicaments for the treatment and/or prophylaxis of CB1 receptor related diseases in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as in adolescent patients. The compounds have the general formula (I) wherein the group Bb represents sulfonyl or carbonyl, and the substituents R, R1, R2 and R3, and the group Aa are defined as shown in the description.

摘要翻译： 本发明摘要本发明涉及作为大麻CB 1受体的有效拮抗剂的4,5-二氢-1H-吡唑化合物的新型医疗用途。 所述化合物特别适用于制备用于治疗和/或预防少年患者中CB 1受体相关疾病的药物和/或用于治疗和/或预防未成年人药物诱导的肥胖的药物 就像青少年患者一样。 化合物具有通式（I），其中基团Bb表示磺酰基或羰基，取代基R 1，R 1，R 2和R 3， SUB>，并且组Aa如说明书所示定义。

公开(公告)号：US20050080125A1

公开(公告)日：2005-04-14

申请号：US10929377

申请日：2004-08-31

申请人： Jochen Antel ,  Gunter Krause ,  Josephus Hubertus Lange ,  Cornelis Gerrit Kruse ,  Peter-Colin Gregory ,  Cathaline Den Besten

发明人： Jochen Antel ,  Gunter Krause ,  Josephus Hubertus Lange ,  Cornelis Gerrit Kruse ,  Peter-Colin Gregory ,  Cathaline Den Besten

IPC分类号： A61K31/415

CPC分类号： A61K31/415

摘要： The present invention relates to a novel medical use of 4,5-dihydro-1H-pyrazole compounds which are potent antagonists of the cannabis CB1-receptor. Said compounds are particularly suitable in the manufacture of medicaments for the treatment and/or prophylaxis of CB1 receptor related diseases in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as in adolescent patients. The compounds have the general formula (I) wherein the group Bb represents sulfonyl or carbonyl, and the substituents R, R1, R2 and R3, and the group Aa are defined as shown in the description.

摘要翻译： 本发明涉及作为大麻CB1受体的有效拮抗剂的4,5-二氢-1H-吡唑化合物的新型医疗用途。 所述化合物特别适用于制备用于治疗和/或预防少年患者中CB1受体相关疾病的药物和/或用于治疗和/或预防青少年和青少年患者中药物诱导的肥胖症的药物。 化合物具有通式（I），其中基团Bb表示磺酰基或羰基，取代基R，R1，R2和R3以及基团Aa如说明书所示定义。

公开(公告)号：US4435834A

公开(公告)日：1984-03-06

申请号：US371425

申请日：1982-04-23

申请人： Gunter Pauli ,  Gunter Krause ,  Erwin Lob

发明人： Gunter Pauli ,  Gunter Krause ,  Erwin Lob

IPC分类号： G07D7/12 ,  G07D7/20 ,  G06K9/00

CPC分类号： G07D7/12 ,  G07D7/20

摘要： The invention discloses a method and an apparatus for determining the condition or genuineness of flat articles, in particular bank-notes. The bank-note passes through a test station in which a large portion of its surface is scanned by a scanning system as it passes through. The electric signals generated by the scanning system are edited in an analyzing electronic circuit and compared with suitable limiting values and a signal denoting a faulty position is generated when a certain tolerance is exceeded. At least one surface portion defined in respect of position and size is selected and the electric signals appropriate to the scanning of this surface portion are compared only with limiting values selected for this portion. Thus, it is possible to check the condition and/or genuineness of flat articles, such as sheets of paper, securities, bank-notes and the like while the general rate of rejection and the exact analysis of preferred portions can be equally set alongside one another, without influencing one another, and examined.

摘要翻译： 本发明公开了一种用于确定扁平制品，特别是纸币的状况或真实性的方法和装置。 钞票通过一个测试台，其中大部分表面在扫描系统通过时被扫描系统扫描。 由扫描系统产生的电信号在分析电子电路中进行编辑，并与适当的限制值进行比较，并且当超过某一公差时，产生表示故障位置的信号。 选择关于位置和大小限定的至少一个表面部分，并且将与该表面部分的扫描相适应的电信号仅与为该部分选择的限制值进行比较。 因此，可以检查诸如纸张，证券，纸币等的扁平制品的状况和/或真实性，同时可以将一般的拒收率和优选部分的确切分析与一个等同地设置在一起 另一个，没有彼此影响，并检查。